Navigation Links
Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
Date:5/20/2013

among the three to receive transplants in both the lumbar and cervical regions.

Of the 9 remaining patients in the trial, three subjects had a long disease course (5.6, 11.6 and 12.7 years of known disease), at the time of their transplantation, likely representing atypical ALS, and have had little change in the trajectory of their disease.  Finally, Dr. Feldman reported, six of the trial patients died of their disease, 7-to-30 months after surgery. Two of these patients had features of bulbar ALS at the time of their transplantation.

"Collectively, these preliminary results suggest that intraspinal stem cell transplantation of ALS subjects, with no bulbar symptoms, early in the course of their disease, could slow disease progression and even allow for functional improvement," Dr. Feldman concluded.  Dr. Feldman is also Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System and an unpaid consultant to Neuralstem. 

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety tr
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
7. Neuralstem Announces Proposed Public Offering
8. Neuralstem to Raise $7.0 Million in Registered Direct Offering
9. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
10. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
11. Neuralstem Secures $8 Million In Debt Financing From Hercules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  The investigational S- equol nutritional supplement may ... such as hot flashes, according to a new peer-reviewed ... .[i] "Current data suggest that women may ... symptoms and possibly additional benefits, such as skin health. ... physicians and health care professionals may consider the use ...
(Date:3/30/2015)... MINNEAPOLIS and ORANGEBURG, N.Y., March 30, 2015 ... Inc. (NASDAQ: VSCI ) shareholders have voted ... held today to approve the previously announced agreement ... "We are pleased with the outcome ... to thank both shareholder groups for approving the ...
(Date:3/30/2015)... March 30, 2015 A team of Chinese ... of a cell-surface receptor that plays a critical role ... discloses many new structural features, which challenge the conventional ... and open a new door for future drug discovery. ... on March 30, the researchers at Shanghai Institute ...
Breaking Medicine Technology:New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 2New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 3New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 4New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 5New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 6
... U.S. Dept. of Defense Continues Study of Copper ... Infections and Improving Indoor Air Quality, NEW ... clinical trails determining the,antimicrobial effectiveness of copper, brass ... Association, announced CDA President Andrew G.,Kireta Sr. ...
... Serious Adverse Reactions, BERKELEY HEIGHTS, N.J., Nov. ... findings from the initial clinical,dosing of G4544, the ... treatment for diseases associated with accelerated bone loss. ... volunteers, has shown good,tolerance with oral bioavailability of ...
Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 2Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 4Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 5
(Date:3/30/2015)... March 30, 2015 Textile Exchange, a ... textile industry, today announced the latest version of its ... certification standard that can be applied to any waterfowl-based ... from hatchling to end product. The goal of the ... animal welfare and to enable traceability so that products ...
(Date:3/30/2015)... On March 11, 2015, Elle Magazine, in ... details six new treatment options for dealing with stubborn, unwanted ... a topical product. The other three technologies use devices to ... or freezing cold ( CoolSculpting ) to kill fat cells. ... to us to permanently remove unwanted fat," says Dr. Simon ...
(Date:3/30/2015)... Vancouver, BC (PRWEB) March 30, 2015 ... ( http://www.idataresearch.com ), the hernia repair market will continue ... market. Growth is occurring primarily due to increasing numbers ... to treat them. , “The significantly large market ... to a generally high ASP. We’re seeing a growing ...
(Date:3/30/2015)... This report studies the global tumor ... to 2019. , Based on the type of ... into four major segments, namely radio-frequency, microwave, cryoablation ... and laser ablation) segments. Moreover, based on type ... classified into three segments, namely, interventional radiology, surgery ...
(Date:3/30/2015)... On March 19th, 2015, in the Hall of Legends ... LiveToBeSober.org hosted the “Fighting Addiction Together” luncheon. Attendees included ... well as other civic leaders and public figures. , ... retired Detroit Lions wide receiver Herman Moore, Live to ... their own personal battles with addiction, Ronald Stevens and ...
Breaking Medicine News(10 mins):Health News:Responsible Down Standard 2.0 Released 2Health News:Responsible Down Standard 2.0 Released 3Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 3Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 2Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2
... Society (APS) is elated that the Senate has approved ... continue cutting-edge research that will lead to innovation, job ... Specifically, APS lauds the bill,s support of research programs ... National Science Foundation and the National Institute of Standards ...
... North Carolina students interested in earning the doctor of optometry ... by College Foundation of North Carolina and the N.C. State Education ... state:, , ... University (Greenville, NC) - 10:00 a.m. - 12:00 noon, ...
... yesterday, exactly six months after Hurricane Ike slammed the ... the lessons learned from Hurricane Rita. , According to ... they would evacuate if a Category 4 hurricane threatened ... 24 percent of residents who left during the Category ...
... Va., LONDON and GENEVA, March 13 Clinical Care ... and NAM, an award-winning community-based HIV information provider, have ... and news from the 5th International AIDS Society Conference ... Cape Town, South Africa, July 19-22, 2009, and the ...
... March 13 Transcept Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of proprietary products that address important ... it will report results for its fourth quarter 2008 ... conference call to review the results will begin at ...
... -- China Sky One Medical, Inc.,("China Sky One ... ), a leading fully,integrated pharmaceutical company producing over-the-counter ... announced that Ms. Xiao-yan Han,China Sky One Medical ... Jaffray,& ChinaVenture Conference in Shanghai and The World ...
Cached Medicine News:Health News:Optometry Career Conferences Set for Five N.C. Campuses in March 2Health News:Rice report shows lessons from Hurricane Rita not practiced during Ike 2Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 2Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 3Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 2Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 3Health News:China Sky One Medical to Attend Two Conferences in March 2Health News:China Sky One Medical to Attend Two Conferences in March 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: